Top

Diabetologia

Published in:

Open Access 01-12-2016 | Article

Investigation of gene–diet interactions in the incretin system and risk of type 2 diabetes: the EPIC-InterAct study

Author: The InterAct Consortium

Published in: Diabetologia | Issue 12/2016

Abstract

Aims/hypothesis

The gut incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) have a major role in the pathophysiology of type 2 diabetes. Specific genetic and dietary factors have been found to influence the release and action of incretins. We examined the effect of interactions between seven incretin-related genetic variants in GIPR, KCNQ1, TCF7L2 and WFS1 and dietary components (whey-containing dairy, cereal fibre, coffee and olive oil) on the risk of type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition (EPIC)-InterAct study.

Methods

The current case-cohort study included 8086 incident type 2 diabetes cases and a representative subcohort of 11,035 participants (median follow-up: 12.5 years). Prentice-weighted Cox proportional hazard regression models were used to investigate the associations and interactions between the dietary factors and genes in relation to the risk of type 2 diabetes.

Results

An interaction (p = 0.048) between TCF7L2 variants and coffee intake was apparent, with an inverse association between coffee and type 2 diabetes present among carriers of the diabetes risk allele (T) in rs12255372 (GG: HR 0.99 [95% CI 0.97, 1.02] per cup of coffee; GT: HR 0.96 [95% CI 0.93, 0.98]); and TT: HR 0.93 [95% CI 0.88, 0.98]). In addition, an interaction (p = 0.005) between an incretin-specific genetic risk score and coffee was observed, again with a stronger inverse association with coffee in carriers with more risk alleles (0–3 risk alleles: HR 0.99 [95% CI 0.94, 1.04]; 7–10 risk alleles: HR 0.95 [95% CI 0.90, 0.99]). None of these associations were statistically significant after correction for multiple testing.

Conclusions/interpretation

Our large-scale case-cohort study provides some evidence for a possible interaction of TCF7L2 variants and an incretin-specific genetic risk score with coffee consumption in relation to the risk of type 2 diabetes. Further large-scale studies and/or meta-analyses are needed to confirm these interactions in other populations.

Available only for authorised users

Holst JJ, Vilsboll T, Deacon CF (2009) The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 297:127–136CrossRefPubMed

Saxena R, Hivert MF, Langenberg C et al (2010) Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 42:142–148CrossRefPubMedPubMedCentral

Mussig K, Staiger H, Machicao F, Haring HU, Fritsche A (2010) Genetic variants affecting incretin sensitivity and incretin secretion. Diabetologia 53:2289–2297CrossRefPubMed

Liu Z, Habener JF (2008) Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem 283:8723–8735CrossRefPubMedPubMedCentral

Loder MK, da Silva Xavier G, McDonald A, Rutter GA (2008) TCF7L2 controls insulin gene expression and insulin secretion in mature pancreatic beta-cells. Biochem Soc Trans 36:357–359CrossRefPubMed

Shu L, Matveyenko AV, Kerr-Conte J, Cho JH, McIntosh CH, Maedler K (2009) Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum Mol Genet 18:2388–2399CrossRefPubMedPubMedCentral

Lyssenko V, Lupi R, Marchetti P et al (2007) Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 117:2155–2163CrossRefPubMedPubMedCentral

Schäfer SA, Tschritter O, Machicao F et al (2007) Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 50:2443–2450CrossRefPubMedPubMedCentral

Schafer SA, Mussig K, Staiger H et al (2009) A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion. Diabetologia 52:1075–1082CrossRefPubMed

10.

Yasuda K, Miyake K, Horikawa Y et al (2008) Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet 40:1092–1097CrossRefPubMed

11.

Unoki H, Takahashi A, Kawaguchi T et al (2008) SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet 40:1098–1102CrossRefPubMed

12.

Tan JT, Nurbaya S, Gardner D, Ye S, Tai ES, Ng DPK (2009) Genetic variation in KCNQ1 associates with fasting glucose and beta-cell function a study of 3,734 subjects comprising three ethnicities living in Singapore. Diabetes 58:1445–1449CrossRefPubMedPubMedCentral

13.

Nilsson M, Holst JJ, Bjorck IME (2007) Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose-equivalent drinks. Am J Clin Nutr 85:996–1004PubMed

14.

Nilsson M, Stenberg M, Frid AH, Holst JJ, Bjorck IM (2004) Glycemia and insulinemia in healthy subjects after lactose equivalent meals of milk and other food proteins: the role of plasma amino acids and incretins. Am J Clin Nutr 80:1246–1253PubMed

15.

Ma J, Stevens JE, Cukier K et al (2009) Effects of a protein preload on gastric emptying, glycemia, and gut hormones after a carbohydrate meal in diet-controlled type 2 diabetes. Diabetes Care 32:1600–1602CrossRefPubMedPubMedCentral

16.

Hall WL, Millward DJ, Long SJ, Morgan LM (2003) Casein and whey exert different effects on plasma amino acid profiles, gastrointestinal hormone secretion and appetite. Br J Nutr 89:239–248CrossRefPubMed

17.

Tessari P, Kiwanuka E, Cristini M et al (2007) Slow versus fast proteins in the stimulation of beta-cell response and the activation of the entero-insular axis in type 2 diabetes. Diabetes Metab Res Rev 23:378–385CrossRefPubMed

18.

Holt SHA, Miller JCB, Petocz P (1997) An insulin index of foods: the insulin demand generated by 1000-kJ portions of common foods. Am J Clin Nutr 66:1264–1276PubMed

19.

Thomsen C, Rasmussen O, Lousen T et al (1999) Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects. Am J Clin Nutr 69:1135–1143PubMed

20.

Thomsen C, Storm H, Holst JJ, Hermansen K (2003) Differential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in patients with type 2 diabetes. Am J Clin Nutr 77:605–611PubMed

21.

Gunnarsson PT, Winzell MS, Deacon CF et al (2006) Glucose-induced incretin hormone release and inactivation are differently modulated by oral fat and protein in mice. Endocrinology 147:3173–3180CrossRefPubMed

22.

Weickert MO, Mohlig M, Koebnick C et al (2005) Impact of cereal fibre on glucose-regulating factors. Diabetologia 48:2343–2353CrossRefPubMed

23.

Najjar AM, Parsons PM, Duncan AM, Robinson LE, Yada RY, Graham TE (2009) The acute impact of ingestion of breads of varying composition on blood glucose, insulin and incretins following first and second meals. Br J Nutr 101:391–398CrossRefPubMed

24.

Johnston KL, Clifford MN, Morgan LM (2003) Coffee acutely modifies gastrointestinal hormone secretion and glucose tolerance in humans: glycemic effects of chlorogenic acid and caffeine. Am J Clin Nutr 78:728–733PubMed

25.

Ley SH, Hamdy O, Mohan V, Hu FB (2014) Prevention and management of type 2 diabetes: dietary components and nutritional strategies. Lancet 383:1999–2007CrossRefPubMedPubMedCentral

26.

Sluijs I, Forouhi NG, Beulens JW et al (2012) The amount and type of dairy product intake and incident type 2 diabetes: results from the EPIC-InterAct Study. Am J Clin Nutr 96:382–390CrossRefPubMed

27.

Buijsse B, Boeing H, Drogan D et al (2015) Consumption of fatty foods and incident type 2 diabetes in populations from eight European countries. Eur J Clin Nutr 69:455–461CrossRefPubMed

28.

The InterAct Consortium (2015) Dietary fibre and incidence of type 2 diabetes in eight European countries: the EPIC-InterAct study and a meta-analysis of prospective studies. Diabetologia 58:1394–1408CrossRefPubMedCentral

29.

The InterAct Consortium (2011) Design and cohort description of the InterAct project: an examination of the interaction of genetic and lifestyle factors on the incidence of type 2 diabetes in the EPIC study. Diabetologia 54:2272–2282CrossRefPubMedCentral

30.

Slimani N, Deharveng G, Unwin I et al (2007) The EPIC nutrient database project (ENDB): a first attempt to standardize nutrient databases across the 10 European countries participating in the EPIC study. Eur J Clin Nutr 61:1037–1056CrossRefPubMed

31.

Cust AE, Skilton MR, van Bakel MM et al (2009) Total dietary carbohydrate, sugar, starch and fibre intakes in the European prospective investigation into cancer and nutrition. Eur J Clin Nutr 63:74CrossRef

32.

Riboli E, Hunt KJ, Slimani N et al (2002) European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 5:1113–1124CrossRefPubMed

33.

Wareham NJ, Jakes RW, Rennie KL et al (2003) Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutr 6:407–413CrossRefPubMed

34.

Haftenberger M, Lahmann PH, Panico S et al (2002) Overweight, obesity and fat distribution in 50- to 64-year-old participants in the European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutr 5:1147–1162CrossRefPubMed

35.

Langenberg C, Sharp SJ, Franks PW et al (2014) Gene-lifestyle interaction and type 2 diabetes: the EPIC interact case-cohort study. PLoS Med 11, e1001647CrossRefPubMedPubMedCentral

36.

Gaulton KJ, Ferreira T, Lee Y et al (2015) Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci. Nat Genet 47:1415–1425CrossRefPubMedPubMedCentral

37.

Willett WC, Howe GR, Kushi LH (1997) Adjustment for total energy intake in epidemiologic studies. Am J Clin Nutr 65:1220S–1228S, discussion 1229S-1231SPubMed

38.

Murphy N, Norat T, Ferrari P et al (2012) Dietary fibre intake and risks of cancers of the colon and rectum in the European prospective investigation into cancer and nutrition (EPIC). PLoS One 7, e39361CrossRefPubMedPubMedCentral

39.

Buckland G, Mayen AL, Agudo A et al (2012) Olive oil intake and mortality within the Spanish population (EPIC-Spain). Am J Clin Nutr 96:142–149CrossRefPubMed

40.

Li J, Ji L (2005) Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity 95:221–227CrossRefPubMed

41.

Fisher E, Boeing H, Fritsche A, Doering F, Joost HG, Schulze MB (2009) Whole-grain consumption and transcription factor-7-like 2 (TCF7L2) rs7903146: gene-diet interaction in modulating type 2 diabetes risk. Br J Nutr 101:478–481

42.

Hindy G, Sonestedt E, Ericson U et al (2012) Role of TCF7L2 risk variant and dietary fibre intake on incident type 2 diabetes. Diabetologia 55:2646–2654CrossRefPubMedPubMedCentral

43.

Wirstrom T, Hilding A, Gu HF, Ostenson CG, Bjorklund A (2013) Consumption of whole grain reduces risk of deteriorating glucose tolerance, including progression to prediabetes. Am J Clin Nutr 97:179–187CrossRefPubMed

44.

Cornelis MC, Qi L, Kraft P, Hu FB (2009) TCF7L2, dietary carbohydrate, and risk of type 2 diabetes in US women. Am J Clin Nutr 89:1256–1262CrossRefPubMedPubMedCentral

45.

Nettleton JA, McKeown NM, Kanoni S et al (2010) Interactions of dietary whole-grain intake with fasting glucose- and insulin-related genetic loci in individuals of European descent: a meta-analysis of 14 cohort studies. Diabetes Care 33:2684–2691CrossRefPubMedPubMedCentral

46.

Faerch K, Pilgaard K, Knop FK et al (2013) Incretin and pancreatic hormone secretion in Caucasian non-diabetic carriers of the TCF7L2 rs7903146 risk T allele. Diabetes Obes Metab 15:91–95CrossRefPubMed

47.

Fernemark H, Jaredsson C, Bunjaku B, Rosenqvist U, Nystrom FH, Guldbrand H (2013) A randomized cross-over trial of the postprandial effects of three different diets in patients with type 2 diabetes. PLoS One 8, e79324CrossRefPubMedPubMedCentral

48.

Franks PW, Pearson E, Florez JC (2013) Gene-environment and gene-treatment interactions in type 2 diabetes: progress, pitfalls, and prospects. Diabetes Care 36:1413–1421CrossRefPubMedPubMedCentral

Title: Investigation of gene–diet interactions in the incretin system and risk of type 2 diabetes: the EPIC-InterAct study
Author: The InterAct Consortium
Publication date: 01-12-2016
Publisher: Springer Berlin Heidelberg
Published in: Diabetologia / Issue 12/2016
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-016-4090-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Investigation of gene–diet interactions in the incretin system and risk of type 2 diabetes: the EPIC-InterAct study

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 12/2016

Erratum to: The epigenetic signature of systemic insulin resistance in obese women

Erratum to: Effective endothelial cell and human pluripotent stem cell interactions generate functional insulin-producing beta cells

Prevalent role of the insulin receptor isoform A in the regulation of hepatic glycogen metabolism in hepatocytes and in mice

A beta cell ATGL-lipolysis/adipose tissue axis controls energy homeostasis and body weight via insulin secretion in mice

Metabolic coupling in pancreatic beta cells: lipolysis revisited

Diabetic retinopathy is not present in newly diagnosed diabetic patients

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page